



*News Release*

FOR IMMEDIATE RELEASE

Contact: Ronald Trahan, APR, Ronald Trahan Associates Inc., 508-359-4005, x108

**Arterial Remodeling Technologies raises \$8.5 million  
in new venture financing round from existing  
investors Matignon Technologies and Amundi Private  
Equity Funds,  
along with new investor InnoBio**

**“Our disruptive technology for fully resorbable  
coronary  
stents is designed to promote natural remodeling  
of an injured artery after angioplasty.”**

Machiel van der Leest, CEO

PARIS, Sept. 21, 2010—[Arterial Remodeling Technologies](#) (“ART”) announced today that it has closed on a new venture financing round of **\$8.5 million** from existing investors **Matignon Technologies** and **Amundi Private Equity Funds**, along with new investor **InnoBio Fund** managed by **CDC Entreprises**. Total investment in the Company is now \$17 million.

In May 2010, ART disclosed the results of an *in vivo* study of 48 porcine arteries implanted with its biodegradable stent, which demonstrated that: (1) the ART stent’s biodegradation is measurable and begins at the first day of implant; (2) the ART stent retains high radial strength, thus maintaining its structural integrity during biodegradation; and, (3) the ART stent causes virtually no inflammation of the blood vessel wall.

“ART has made very significant progress over the past 22 months, and this new cash infusion will accelerate the development of our breakthrough approach of simultaneously balancing **biocompatibility**, **biomechanics**, and **bioresorption** within a **bioresorbable PLA** (polylactic acid) stent,” said **Machiel van der Leest, CEO**, who previously was a co-founder and Chief Technology Officer of Minvasys. During his career he has developed and successfully introduced **15 Class III medical devices**, which required pre-market approval and a scientific review to ensure safety and effectiveness.

“We are very enthusiastic about the prospects for ART—because we believe that bioresorbable stents are the future of interventional cardiology, and that ART is well-positioned in this sector,” said **Philippe Boucheron**, Investment Manager, InnoBio Fund.

Earlier this year, validating data regarding ART’s next-generation bioresorbable stent was published in the January 2010 special supplement of *EuroIntervention*, a peer-reviewed journal. The paper was authored by Antoine Lafont, M.D., Ph.D., Head, Interventional Cardiology Department, Georges Pompidou Hospital (Paris); Past Chairman, Interventional Cardiology

Group, European Society of Cardiology (ESC).

ART's bioresorbable stent is designed to be delivered by conventional stenting techniques, is balloon-expandable, and meets the market standard of 6-French compatibility. ART's novel biopolymers have been developed in conjunction with one of the world's leading authorities in polymer chemistry, **Professor Michel Vert**, who is Former Director of the Research Center for Artificial Biopolymers at France's National Center for Scientific Research (Centre National de Recherche Scientifique/CNRS).

**InnoBio** is a €140 million French venture capital fund managed by CDC Entreprises. Its subscribers include some of the leading international pharmaceutical companies. The fund's mission is to make direct equity and quasi-equity investments in Life Sciences companies with innovative technology products and services. Innobio's investor team is led by Laurent Arthaud.

**CDC Entreprises** is a management company authorized by France's financial market regulator, the AMF, and a wholly-owned subsidiary of the Caisse des Dépôts. The largest subscriber of CDC Entreprises' funds is the Caisse des Dépôts group (notably the "Fonds Stratégique d'Investissement", FSI). Other subscribers include public and private financial institutions and industry firms.

**Matignon Investissement et Gestion** is a European, independent management company with approximately €200 million under management, including its recent vehicle, **Matignon Technologies II FCPR**, one of the largest European funds dedicated primarily to medical technologies.

**Amundi Private Equity Funds** (Amundi PEF) has assets under management of €4.2 billion. With over 60 investment professionals based in Paris, Bucharest, Casablanca, Tunis and Warsaw, Amundi PEF helps companies at every stage of their growth, from creation to transmission, and forms long-standing and trusting relationships with its clients. Amundi PEF is an expertise of the Amundi Group.

#### [About Arterial Remodeling Technologies \("ART"\)](#)

Arterial Remodeling Technologies ("ART") is developing bioresorbable coronary polymer stents that are designed to promote the natural remodeling of an injured artery after angioplasty. The Company's technology is based on intellectual property originating from three esteemed institutions: the **Cleveland Clinic**; the French national research institute, **CNRS** (Centre National de Recherche Scientifique), Montpellier, France; and, **Descartes University**, Paris.

#####